In this regard, several studies have been conducted, in vitro and in vivo, which have reported a controversial role of bFGF in prostate cancer with regard to both its cellular localization and the clinicopathological phenotype and prognosis. This evidence concerns the gene FGF2 and prostate carcinoma.